Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)

Dr. Richard A. Furie

Rheumatology
North Shore-Lij Medical PC
330 Community Dr, 
Manhasset, NY 
43 Years of Experience
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
North Shore-Lij Medical PC
330 Community Dr, 
Manhasset, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Furie is a Rheumatologist in Manhasset, New York. Dr. Furie has been practicing medicine for over 43 years and is rated as an Experienced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Cutaneous Lupus Erythematosus (CLE), and Discoid Lupus Erythematosus (DLE).

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in NY
Hospital Affiliations
North Shore University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Northwell Health
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

NORTH SHORE-LIJ MEDICAL PC
330 Community Dr, Manhasset, NY 11030
Other Locations
NORTH SHORE-LIJ MEDICAL PC
865 Northern Blvd, Suite 102, Great Neck, NY 11021
NORTH SHORE-LIJ MEDICAL PC
350 Community Dr, Manhasset, NY 11030
NORTH SHORE-LIJ MEDICAL PC
300 Community Dr, Manhasset, NY 11030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: November 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

152 Total Publications

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Reply.
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Reply.
Journal: The New England journal of medicine
Published: July 23, 2025
Similar Doctors
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Roman Zuckerman
Rheumatology
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Roman Zuckerman
Rheumatology

Valley Physician Services PC

108 Jackson St, Apt 6b, 
Hoboken, NJ 
 (18.0 miles away)
800-825-5391
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Roman Zuckerman is a Rheumatologist in Hoboken, New Jersey. Dr. Zuckerman is rated as an Advanced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Juvenile Temporal Arteritis, Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, and Giant Cell Arteritis (GCA). Dr. Zuckerman is currently accepting new patients.

Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Howard M. Belmont
Rheumatology
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Howard M. Belmont
Rheumatology

New York University

560 1st Ave, 
New York, NY 
 (14.5 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances

Howard Belmont is a Rheumatologist in New York, New York. Dr. Belmont is rated as a Distinguished provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Lupus Nephritis, Systemic Lupus Erythematosus (SLE), Osteoporosis, and Postmenopausal Osteoporosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Furie's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile